Clinical Activity of Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib; Interim Results of a Phase 1b/2 Study in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) (Lee et al., ASCO 2020 Virtual Annual Meeting)